- Lasofoxifene
drugbox
IUPAC_name = (5R,6S)-6-phenyl-5- [4-(2-pyrrolidin-1-ylethoxy)phenyl] -5,6,7,8-tetrahydronaphthalen-2-ol
width = 202
CAS_number = 180916-16-9
ATC_prefix = G03
ATC_suffix = XC
PubChem = 216416
DrugBank =
C=28 | H=31 | N=1 | O=2
molecular_weight = 413.55 or 563.64 (with tartrate)
bioavailability =
metabolism =
excretion =
pregnancy_category =
legal_status =
routes_of_administration =Lasofoxifene (INN) (proposed tradename Fablyn) is a
selective estrogen receptor modulator (SERM) which is under development byBristol-Myers Squibb for the prevention and treatment ofosteoporosis and for the treatment of vaginal atrophycite journal | author = Gennari L, Merlotti D, Martini G, Nuti R | title = Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis | journal = Expert Opin Investig Drugs | volume = 15 | issue = 9 | pages = 1091–103 | year = 2006 | pmid = 16916275 | doi = 10.1517/13543784.15.9.1091 | issn = ] , and the result of an exclusive research collaboration with Ligand Pharmaceuticals(LGND) .In September 2005,
Bristol-Myers Squibb received a non-approvable letter from the U.S.Food and Drug Administration regarding lasofoxifene (trade name Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis.On January 2008, Ligand Pharmaceuticals, through its marketing partner,
Bristol-Myers Squibb , submitted a New Drug Application for lasofoxifene, which is now to be marketed under the tradename Fablyn.References
External links
*
Wikimedia Foundation. 2010.
